Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 in ALS
NCT02059759Phase 2Completed
- Sponsor
- CHU Nîmes
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in amyotrophic lateral sclerosis (ALS), sponsored by CHU Nîmes. Started Sep 2015; status: completed.
02
Drugs
aldesleukin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02059759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059759.